To become a pharmaceutical brand with global influence is the corporate vision of Yangtze River Pharmaceutical Group, in order to achieve this goal, the company has continued to pay close attention to product quality for many years, promote the global development path with quality control as the guide, and continuously expand the brand influence.
Yangtze River Pharmaceutical Group's quality management model is the "quality management cockpit", on this model diagram like a car steering wheel, it is clearly marked that the core of quality management is the corporate mission of Yangtze River Pharmaceutical Group - "seek and forge ahead, protect all beings", "do not let patients bear risks", "do not let risks escalate", "do not transfer risks to the local government" The "three nos" are the backbone, and continuous questioning, continuous identification, continuous control and continuous review form a closed-loop link to ensure that product quality is effectively controllable.
In order to truly make good use of the "quality management cockpit", Yangtze River Pharmaceutical Group has made great efforts in all aspects of enterprise management, formulated product quality internal control standards that are higher than the national legal standards, and strictly referred to the implementation of international industry standards such as GMP GSP, successively integrated international standards such as quality, environment, occupational health and safety management, measurement management, laboratory accreditation, etc., and introduced advanced management concepts and tools such as SDCA PDCA, ** circle rule, risk management, and ambulatory management, and insisted on carrying out it twice a year. Quality Month", mass quality management QC group activities, etc., have created a vivid atmosphere of "everyone grasps quality" within the enterprise.
Under the guidance of solid quality management, Yangtze River Pharmaceutical Group has steadily promoted the process of globalization, and the company has 5 workshops, 7 preparations and 1 extract that have passed the EU GMP certification, and 2 workshops, 1 API and 1 preparation have passed the Australian TGA GMP certification. A total of 102 varieties of the company's products have been exported to 38 countries or regions, of which 98 varieties have been exported to 31 countries or regions along the "Belt and Road"; 113 specifications have been approved for registration in 35 countries or regions. From January to September 2023, the export value of more than 10 traditional Chinese medicines and APIs produced by the group, such as Lanqin oral liquid and tamoxifen citrate, increased by 299% year-on-year in the Russian market, and won the title of "2023 Chinese Brand Loved by Foreigners".
While promoting its products abroad, Yangtze River Pharmaceutical Group also actively participates in the promotion of traditional Chinese medicine culture. The group undertook the research work of 15 plant monographs of Chinese herbal medicines "European Pharmacopoeia", among which 5 varieties of Chinese herbal medicine "Polyphytes knotweed", "Saffron seeds", "Japanese knotweed", "Houttuynia cordata" and "Zeeland" have been included in the "European Pharmacopoeia".
In addition, Yangtze River Pharmaceutical Group has also cooperated with China Pharmaceutical University, emlyon business school and other institutions to build an education center for the integration of production and education for studying abroad, and an innovation center for the integration of industry and education in health, etc., to strengthen international exchanges in the field of medicine, customize and train international high-end pharmaceutical talents, and help spread the culture of traditional Chinese medicine and promote the development of the pharmaceutical industry.